Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.
Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Medication. This report contains market size and forecasts of Myotonic Dystrophy Medication in global, including the following market information:
Global Myotonic Dystrophy Medication Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Myotonic Dystrophy Medication market was valued at US$ 43 million in 2022 and is projected to reach US$ 50 million by 2029, at a CAGR of 2.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.
We surveyed the Myotonic Dystrophy Medication companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myotonic Dystrophy Medication Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Myotonic Dystrophy Medication Market Segment Percentages, by Type, 2022 (%)
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Global Myotonic Dystrophy Medication Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Myotonic Dystrophy Medication Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Other
Global Myotonic Dystrophy Medication Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Myotonic Dystrophy Medication Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myotonic Dystrophy Medication revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Myotonic Dystrophy Medication revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Outline of Major Chapters:
Chapter 1: Introduces the definition of Myotonic Dystrophy Medication, market overview.
Chapter 2: Global Myotonic Dystrophy Medication market size in revenue.
Chapter 3: Detailed analysis of Myotonic Dystrophy Medication company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Myotonic Dystrophy Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Myotonic Dystrophy Medication Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Myotonic Dystrophy Medication Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myotonic Dystrophy Medication Overall Market Size
2.1 Global Myotonic Dystrophy Medication Market Size: 2022 VS 2030
2.2 Global Myotonic Dystrophy Medication Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Myotonic Dystrophy Medication Players in Global Market
3.2 Top Global Myotonic Dystrophy Medication Companies Ranked by Revenue
3.3 Global Myotonic Dystrophy Medication Revenue by Companies
3.4 Top 3 and Top 5 Myotonic Dystrophy Medication Companies in Global Market, by Revenue in 2022
3.5 Global Companies Myotonic Dystrophy Medication Product Type
3.6 Tier 1, Tier 2 and Tier 3 Myotonic Dystrophy Medication Players in Global Market
3.6.1 List of Global Tier 1 Myotonic Dystrophy Medication Companies
3.6.2 List of Global Tier 2 and Tier 3 Myotonic Dystrophy Medication Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Myotonic Dystrophy Medication Market Size Markets, 2022 & 2030
4.1.2 Sodium Channel Blocker
4.1.3 Tricyclic Antidepressant
4.1.4 Other
4.2 By Type - Global Myotonic Dystrophy Medication Revenue & Forecasts
4.2.1 By Type - Global Myotonic Dystrophy Medication Revenue, 2018-2023
4.2.2 By Type - Global Myotonic Dystrophy Medication Revenue, 2024-2030
4.2.3 By Type - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Myotonic Dystrophy Medication Market Size, 2022 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application - Global Myotonic Dystrophy Medication Revenue & Forecasts
5.2.1 By Application - Global Myotonic Dystrophy Medication Revenue, 2018-2023
5.2.2 By Application - Global Myotonic Dystrophy Medication Revenue, 2024-2030
5.2.3 By Application - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Myotonic Dystrophy Medication Market Size, 2022 & 2030
6.2 By Region - Global Myotonic Dystrophy Medication Revenue & Forecasts
6.2.1 By Region - Global Myotonic Dystrophy Medication Revenue, 2018-2023
6.2.2 By Region - Global Myotonic Dystrophy Medication Revenue, 2024-2030
6.2.3 By Region - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Myotonic Dystrophy Medication Revenue, 2018-2030
6.3.2 US Myotonic Dystrophy Medication Market Size, 2018-2030
6.3.3 Canada Myotonic Dystrophy Medication Market Size, 2018-2030
6.3.4 Mexico Myotonic Dystrophy Medication Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Myotonic Dystrophy Medication Revenue, 2018-2030
6.4.2 Germany Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.3 France Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.4 U.K. Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.5 Italy Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.6 Russia Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.7 Nordic Countries Myotonic Dystrophy Medication Market Size, 2018-2030
6.4.8 Benelux Myotonic Dystrophy Medication Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Myotonic Dystrophy Medication Revenue, 2018-2030
6.5.2 China Myotonic Dystrophy Medication Market Size, 2018-2030
6.5.3 Japan Myotonic Dystrophy Medication Market Size, 2018-2030
6.5.4 South Korea Myotonic Dystrophy Medication Market Size, 2018-2030
6.5.5 Southeast Asia Myotonic Dystrophy Medication Market Size, 2018-2030
6.5.6 India Myotonic Dystrophy Medication Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Myotonic Dystrophy Medication Revenue, 2018-2030
6.6.2 Brazil Myotonic Dystrophy Medication Market Size, 2018-2030
6.6.3 Argentina Myotonic Dystrophy Medication Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Myotonic Dystrophy Medication Revenue, 2018-2030
6.7.2 Turkey Myotonic Dystrophy Medication Market Size, 2018-2030
6.7.3 Israel Myotonic Dystrophy Medication Market Size, 2018-2030
6.7.4 Saudi Arabia Myotonic Dystrophy Medication Market Size, 2018-2030
6.7.5 UAE Myotonic Dystrophy Medication Market Size, 2018-2030
7 Myotonic Dystrophy Medication Companies Profiles
7.1 Lupin
7.1.1 Lupin Company Summary
7.1.2 Lupin Business Overview
7.1.3 Lupin Myotonic Dystrophy Medication Major Product Offerings
7.1.4 Lupin Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.1.5 Lupin Key News & Latest Developments
7.2 Teva
7.2.1 Teva Company Summary
7.2.2 Teva Business Overview
7.2.3 Teva Myotonic Dystrophy Medication Major Product Offerings
7.2.4 Teva Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.2.5 Teva Key News & Latest Developments
7.3 ANI Pharmaceuticals
7.3.1 ANI Pharmaceuticals Company Summary
7.3.2 ANI Pharmaceuticals Business Overview
7.3.3 ANI Pharmaceuticals Myotonic Dystrophy Medication Major Product Offerings
7.3.4 ANI Pharmaceuticals Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.3.5 ANI Pharmaceuticals Key News & Latest Developments
7.4 Mylan
7.4.1 Mylan Company Summary
7.4.2 Mylan Business Overview
7.4.3 Mylan Myotonic Dystrophy Medication Major Product Offerings
7.4.4 Mylan Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.4.5 Mylan Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Myotonic Dystrophy Medication Major Product Offerings
7.5.4 Novartis Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Sun Pharma
7.6.1 Sun Pharma Company Summary
7.6.2 Sun Pharma Business Overview
7.6.3 Sun Pharma Myotonic Dystrophy Medication Major Product Offerings
7.6.4 Sun Pharma Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.6.5 Sun Pharma Key News & Latest Developments
7.7 Mallinckrodt
7.7.1 Mallinckrodt Company Summary
7.7.2 Mallinckrodt Business Overview
7.7.3 Mallinckrodt Myotonic Dystrophy Medication Major Product Offerings
7.7.4 Mallinckrodt Myotonic Dystrophy Medication Revenue in Global Market (2018-2023)
7.7.5 Mallinckrodt Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Myotonic Dystrophy Medication Market Opportunities & Trends in Global Market
Table 2. Myotonic Dystrophy Medication Market Drivers in Global Market
Table 3. Myotonic Dystrophy Medication Market Restraints in Global Market
Table 4. Key Players of Myotonic Dystrophy Medication in Global Market
Table 5. Top Myotonic Dystrophy Medication Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Myotonic Dystrophy Medication Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Myotonic Dystrophy Medication Revenue Share by Companies, 2018-2023
Table 8. Global Companies Myotonic Dystrophy Medication Product Type
Table 9. List of Global Tier 1 Myotonic Dystrophy Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myotonic Dystrophy Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Myotonic Dystrophy Medication Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Myotonic Dystrophy Medication Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Myotonic Dystrophy Medication Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Myotonic Dystrophy Medication Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Myotonic Dystrophy Medication Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Myotonic Dystrophy Medication Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Myotonic Dystrophy Medication Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Myotonic Dystrophy Medication Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Myotonic Dystrophy Medication Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Myotonic Dystrophy Medication Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Myotonic Dystrophy Medication Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Myotonic Dystrophy Medication Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Myotonic Dystrophy Medication Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Myotonic Dystrophy Medication Revenue, (US$, Mn), 2024-2030
Table 30. Lupin Company Summary
Table 31. Lupin Myotonic Dystrophy Medication Product Offerings
Table 32. Lupin Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 33. Lupin Key News & Latest Developments
Table 34. Teva Company Summary
Table 35. Teva Myotonic Dystrophy Medication Product Offerings
Table 36. Teva Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 37. Teva Key News & Latest Developments
Table 38. ANI Pharmaceuticals Company Summary
Table 39. ANI Pharmaceuticals Myotonic Dystrophy Medication Product Offerings
Table 40. ANI Pharmaceuticals Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 41. ANI Pharmaceuticals Key News & Latest Developments
Table 42. Mylan Company Summary
Table 43. Mylan Myotonic Dystrophy Medication Product Offerings
Table 44. Mylan Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 45. Mylan Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Myotonic Dystrophy Medication Product Offerings
Table 48. Novartis Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Sun Pharma Company Summary
Table 51. Sun Pharma Myotonic Dystrophy Medication Product Offerings
Table 52. Sun Pharma Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 53. Sun Pharma Key News & Latest Developments
Table 54. Mallinckrodt Company Summary
Table 55. Mallinckrodt Myotonic Dystrophy Medication Product Offerings
Table 56. Mallinckrodt Myotonic Dystrophy Medication Revenue (US$, Mn) & (2018-2023)
Table 57. Mallinckrodt Key News & Latest Developments
List of Figures
Figure 1. Myotonic Dystrophy Medication Segment by Type in 2022
Figure 2. Myotonic Dystrophy Medication Segment by Application in 2022
Figure 3. Global Myotonic Dystrophy Medication Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Myotonic Dystrophy Medication Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Myotonic Dystrophy Medication Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Myotonic Dystrophy Medication Revenue in 2022
Figure 8. By Type - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 9. By Application - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 10. By Type - Global Myotonic Dystrophy Medication Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 12. By Application - Global Myotonic Dystrophy Medication Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 14. By Region - Global Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 15. By Country - North America Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 16. US Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 20. Germany Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 21. France Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 28. China Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 32. India Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 34. Brazil Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Myotonic Dystrophy Medication Revenue Market Share, 2018-2030
Figure 37. Turkey Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Myotonic Dystrophy Medication Revenue, (US$, Mn), 2018-2030
Figure 41. Lupin Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Teva Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. ANI Pharmaceuticals Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Mylan Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sun Pharma Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Mallinckrodt Myotonic Dystrophy Medication Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
